Stryker Enters China Race With Trauson Bid

The acquisition of Trauson would give Stryker deep roots into the untapped territories of China’s $1.5 billion orthopedics industry, the so-called second- and third-tier markets in lesser developed areas where multinationals haven’t been able to access.

More from Archive

More from Medtech Insight